Here are some updates since our last IPR update:

HUMIRA

On November 6, 2017, Sandoz filed an IPR Petition challenging AbbVie’s U.S. Patent No. 9,187,559 (IPR2018-00156).  The ‘559 patent is directed to a method for treating idiopathic inflammatory bowel disease.

RITUXAN

On November 6, 2017, the Board denied institution of an IPR on Pfizer’s petition (IPR2017-01167) challenging Biogen’s U.S. Patent No. 8,557,244 directed to methods for treating diffuse large cell lymphoma.

On November 6, 2017, the Board instituted an IPR on Pfizer’s petition (IPR2017-01168) challenging Biogen’s U.S. Patent No. 8,821,873 also directed to methods for treating diffuse large cell lymphoma.

On November 13, 2017, the Board denied institution of an IPR on Pfizer’s petition (IPR2017-01166) challenging Biogen’s U.S. Patent No. 8,329,172 directed to methods for treating low grade B-cell non-Hodgkin’s lymphoma.